Sileo (Dexmedetomidine Oromucosal Gel) for Canine Noise Aversion: Dosing, Efficacy, and Safety

Bottom line

Sileo (dexmedetomidine oromucosal gel) is the first and only FDA-approved treatment for noise aversion in dogs (NADA 141-456) [1]. It is a synthetic alpha-2 adrenergic agonist applied to the oral mucosa — absorbed transmucosally, not swallowed — 30 to 60 minutes before or at the onset of a noise event, producing anxiolysis at subsedative doses rather than the general sedation seen with injectable alpha-2 agonists [1][3]. It is best positioned as a rapid-onset, short-duration option for anticipated discrete triggers such as fireworks and thunderstorms [2]; dose it by body weight as a number of dosing dots and pair it with a behavior-modification plan.

Drug facts

Sileo is a synthetic alpha-2 adrenoceptor agonist; each mL contains 0.09 mg dexmedetomidine (equivalent to 0.1 mg dexmedetomidine hydrochloride) [1]. As an alpha-2 agonist it reduces central noradrenergic output and CNS sympathetic tone, which is the basis for its anxiolytic effect. The Merck Veterinary Manual classes dexmedetomidine oral gel as a rapid-onset, short-duration option well suited to anticipated discrete triggers such as fireworks and thunderstorms [2].

• Class / MOA: alpha-2 adrenergic agonist [1][2]; decreases CNS noradrenergic output and sympathetic drive.
• Formulation: a multi-dose oral syringe delivering measured "dosing dots" (each dot = 0.25 mL) for oromucosal (transmucosal) administration [1].
• FDA status: approved for the treatment of noise aversion in dogs — the first labeled indication of its kind (NADA 141-456) [1].
• Key contraindications: severe cardiovascular, respiratory, hepatic, or renal disease; shock; severe debilitation or stress [1].

Dosing and administration

Dose from the label only. Sileo is dosed at 125 mcg/m² body surface area, delivered as a weight-based number of dosing dots from the multi-dose syringe (each dot = 0.25 mL) [1]. The label's weight bands run from 1 dot at the low end (approximately 4.4–12.1 lb / 2.0–5.5 kg) up to 10 dots for the largest dogs (approximately 196–220 lb); use the printed dosing-dot chart to match the dog's current weight to its dot count rather than estimating [1].

Administration is the load-bearing step:

• Apply the gel onto the oral mucosa between the dog's cheek and gum. It is absorbed across the oral mucosa and therefore must NOT be swallowed or given with food [1].
• Give approximately 30–60 minutes before the anticipated noise, or at the first sign of anxiety [1].
• A dose may be repeated after at least a 2-hour pause; no more than 5 doses may be given during one noise event [1].
• Wear impermeable disposable gloves when administering to avoid transdermal exposure [1].

Efficacy evidence

The pivotal evidence is a randomised, double-blind, placebo-controlled field study. Korpivaara et al. (2017, Veterinary Record) enrolled 182 dogs with a history of fireworks-associated fear and treated them on New Year's Eve; an owner-rated "good" or "excellent" effect was reported for 72% of dexmedetomidine-treated dogs versus 37% of placebo dogs, with an overall treatment effect that was highly significant (P<0.0001) and no local-tolerance or clinical safety concerns at the subsedative dose [3].

Field/real-world evidence supports repeated use across a season. Gruen et al. (2020, Veterinary Record) evaluated repeated dosing over a series of noise events: within-event anxiety scores fell (median 11-point reduction, P<0.0001), and the odds of needing treatment decreased by about 25% per successive event (odds ratio 0.75) — consistent with the drug supporting, rather than blunting, behavioral learning [4]. As of 2026, these two Veterinary Record studies remain the primary controlled efficacy base.

Adverse effects

At the labeled transmucosal dose the effect profile is mild and largely local. Pale mucous membranes at and around the application site are frequently seen; this reflects local alpha-2-mediated vasoconstriction where the gel contacts the mucosa, is expected, and is not a sign of systemic hypoperfusion at label dosing [1]. Mild sedation or drowsiness occurs and is dose-related — uncommon at the labeled dose but reported in up to roughly one-third of dogs at higher-than-labeled doses — and transient emesis can occur [1].

The alpha-2 class cardiovascular effects — bradycardia and reduced cardiac output — are minimized at the low transmucosal anxiolytic dose but become relevant if the gel is swallowed in quantity or the dog is overdosed; sensitive dogs may show a drop in heart rate and body temperature [1]. Clinically significant alpha-2 effects are reversible in principle with an alpha-2 antagonist (atipamezole).

Contraindications and interactions

Do not use Sileo in dogs with severe cardiovascular, respiratory, hepatic, or renal disease, or in shock, severe debilitation, or stress [1]. Use caution when combining it with other CNS depressants or other alpha-2 agonists — including injectable dexmedetomidine/medetomidine and clonidine — where sedative and cardiovascular effects are additive [1]. Sileo is for dogs only and is an event-based anxiolytic; it is not a chronic daily medication for the underlying anxiety disorder. Owner-handling caution matters: wear impermeable gloves and avoid skin and eye contact with the gel [1].

Monitoring and owner counseling

Correct application technique is the number-one real-world failure point. The gel must sit on the oral mucosa between cheek and gum and must not be swallowed; owners commonly under-dose by mis-counting dots or effectively deactivate the drug by mixing it with food or letting the dog swallow it [1]. Confirm the owner can lock and read the syringe's dot markings and demonstrate placement before they leave.

Counsel that Sileo is one part of a plan: pair it with a structured behavior-modification and noise-desensitization program, and manage frequent, unpredictable triggers with a maintenance strategy rather than escalating event dosing [2]. Set expectations for pale gums and mild drowsiness so these are not mistaken for adverse events, and reinforce the at-least-2-hour interval and the 5-dose-per-event ceiling [1].

Where Sileo sits versus alternatives

For anticipated, discrete noise events, the Merck Veterinary Manual groups Sileo with other rapid-onset situational agents — trazodone, clonidine, and short-acting benzodiazepines such as alprazolam — and reserves daily/maintenance drugs for frequent, unpredictable triggers [2].

• vs trazodone: trazodone is an oral situational agent with a slower onset (roughly 90–120 minutes) and a longer 4–6 hour duration [2]; Sileo's transmucosal route gives a faster, shorter, more event-targeted window and no swallowing requirement.
• vs gabapentin: gabapentin is another oral situational option, useful for its sedative/anxiolytic effect but with variable individual response and off-label for this use; Sileo is the only agent in this group carrying an on-label noise-aversion indication [1].
• vs tasipimidine: tasipimidine is a newer oral alpha-2-like anxiolytic for canine noise aversion and separation anxiety — a systemic oral alternative in the same receptor family.
• vs clonidine: clonidine is an off-label oral alpha-2 adjunct often layered onto situational or maintenance protocols.
• vs daily SSRIs: for the underlying disorder rather than the event, a daily SSRI such as fluoxetine targets the baseline anxiety, with Sileo and the situational agents above used on top for individual events.

Frequently Asked Questions

Is there a Sileo dose chart, and how many dots does my patient get? Dose from the label. Sileo is dosed at 125 mcg/m² body surface area, delivered as a weight-based number of dosing dots on the multi-dose syringe (each dot = 0.25 mL). The chart runs from 1 dot for the smallest dogs (about 4.4–12.1 lb) up to 10 dots for the largest; match the dog's current weight to the printed dot count rather than estimating [1].

How often can you repeat Sileo during an event? A dose may be repeated after at least a 2-hour pause, and no more than 5 doses may be given during a single noise event. Redose for a prolonged or renewed trigger within that ceiling; do not shorten the interval [1].

Sileo vs trazodone for fireworks — which is better? Both are situational. Sileo is applied transmucosally with a fast onset and a short, event-targeted window and carries the only on-label noise-aversion indication; trazodone is oral with a slower onset (roughly 90–120 minutes) and a longer 4–6 hour duration that can suit longer or less predictable events. Choose on timing control and whether reliable oromucosal dosing is feasible [1][2].

Does Sileo sedate the dog? At the labeled dose the intended effect is anxiolysis without general sedation — the pivotal trial used subsedative doses. Mild drowsiness can occur and is dose-related; sedation becomes common (up to about a third of dogs) at higher-than-labeled doses, which is one reason accurate dot counting matters [3][1].

Can Sileo be combined with trazodone or gabapentin? These combinations are used clinically but are not label-studied, and sedative and cardiovascular effects are additive with other CNS depressants. If layering, account for the additive sedation, watch for excessive drowsiness or bradycardia, and avoid stacking multiple alpha-2 agents [1].

Why are the gums pale after Sileo? Pale mucous membranes at the application site are frequently seen and expected — they reflect local alpha-2-mediated vasoconstriction where the gel contacts the mucosa, not systemic hypoperfusion at labeled dosing. Counsel owners in advance so it is not mistaken for an adverse event [1].

Can Sileo be used daily or long-term? No — it is an event-based anxiolytic for discrete, anticipated noise events, not a maintenance drug. Frequent or unpredictable triggers and the underlying anxiety disorder are better managed with a behavior-modification plan plus a daily medication such as an SSRI, for example fluoxetine [2].

What if the dog swallows the gel instead of absorbing it? Swallowing defeats transmucosal absorption and reduces efficacy, and a swallowed larger quantity raises the risk of systemic alpha-2 effects such as bradycardia and sedation. Re-demonstrate placement between cheek and gum, confirm the gel is not given with food, and re-counsel technique — application error is the most common real-world failure [1].